RedHill Biopharma's (RDHL) Movantik Added To Medicare Part D Formulary
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Redhill Biopharma (RDHL) PT Lowered to $10 at BTIG
December 1, 2021 6:00 AM ESTBTIG analyst Robert Hazlett lowered the price target on Redhill Biopharma (NASDAQ: RDHL) to $10.00 (from $16.00) while maintaining a Buy rating.... More
RedHill Biopharma (RDHL) Tops Q3 EPS by 16c
November 30, 2021 7:05 AM ESTRedHill Biopharma (NASDAQ: RDHL) reported Q3 EPS of ($0.05), $0.16 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $24.52 million.
For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.
... More